HDAC9 and pancreatic neoplasm: Therefore, after assessing that VPA, a class I/IIa HDAC inhibitor, did increase acetylation of histone H3 (Supplementary Fig. S1), we investigated whether such treatment, could upregulate PD-L1 in two pancreatic cancer cell lines, PaCa44 and PT45.